Skip to main content
. 2020 Aug 4;9(16):e015042. doi: 10.1161/JAHA.119.015042

Figure 2. Specialty of prescriber.

Figure 2

Monotherapy: angiotensin‐converting enzyme inhibitor/angiotensin receptor blocker/angiotensin receptor neprilysin inhibitors or beta‐blockers or mineralocorticoid receptor antagonist; dual therapy: (angiotensin‐converting enzyme inhibitor/angiotensin receptor blocker/angiotensin receptor neprilysin inhibitors+beta‐blockers) or (mineralocorticoid receptor antagonist+beta‐blockers) or (angiotensin‐converting enzyme inhibitor/angiotensin receptor blocker/angiotensin receptor neprilysin inhibitors+mineralocorticoid receptor antagonist); triple therapy: (beta‐blockers+angiotensin‐converting enzyme inhibitor/angiotensin receptor blocker/angiotensin receptor neprilysin inhibitors+mineralocorticoid receptor antagonist). Includes all encounters; not restricted to physician office visits. Specialty categories reflect the first prescription relating to the highest treatment intensity (monotherapy, dual therapy, or triple therapy) reached in the year after hospitalization. “Other” category includes >50 additional provider classifications, with none prescribing to >0.3% of patients who received medication. ACEI indicates angiotensin‐converting enzyme inhibitor; ARB, angiotensin receptor blocker; ARNI, angiotensin receptor‐neprilysin inhibitors; BB, beta‐blockers; MRA, mineralocorticoid receptor antagonist; NP, nurse practitioner; PA, physician’s assistant; PCP, primary care physician.